Kiyohiro Nishikawa
Chuo, 1030023, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.
Journal: The Journal of dermatology
Published: March 14, 2022
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Journal: Modern rheumatology
Published: July 09, 2021
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
Journal: Journal of gastroenterology and hepatology
Published: November 17, 2020
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice.
Journal: Intestinal research
Published: March 20, 2019
Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: September 06, 2017
A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines through activation of aryl hydrocarbon receptor.
Journal: Molecular cancer therapeutics
Published: December 20, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026